Rivaroxaban for preventing adverse outcomes after acute management of acute coronary
KEYWORDS: rivaroxaban, patients, aspirin, treatment, committee, coronary, company, acute, erg, trial, acute coronary, syndrome, coronary syndrome, events, dose

to 2.02 95% CI 0.85 to 2.24 95% CI 0.85 to 2.01 p=0.403 p=0.190 p=0.225 Abbreviations: bd, twice daily; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MI, myocardial infarction; mITT, modified intention to treat 3.9 The company did not report any results in relation to treatment compliance or premature discontinuation of study treatments for the licensed population because data were not available at the time of submission. For the total trial population, among patients who had at least 1 dose of a study drug, premature discontinuation of treatment occurred in 26.9% (1,376 out of 5,115) of patients having the 2.5 mg twice-daily dose of rivaroxaban, 29.4% (1,504 out of 5,110) of patients having the 5 mg twice-daily dose of rivaroxaban and 26.4% (1,351 out of 5,125) of patients having placebo. No statistical comparisons were reported for these differences. The most common reasons for discontinuation of study treatment were adverse events (rivaroxaban 2.5 mg twice daily 8.8%; rivaroxaban 5 mg twice daily 10.9%; placebo 7.3%), consent withdrawal (rivaroxaban 2.5 mg twice daily 4.7%; rivaroxaban 5 mg twice daily 4.3%; placebo 4.3%) and 'other' (rivaroxaban 2.5 mg twice daily 11.5%; rivaroxaban 5 mg twice daily 11.3%; placebo 11.8%). 3.10 Of the
